Alcon Labs' Betoptic
Executive Summary
Regulatory review period for the ocular antihypertensive (betaxolol) was 1,905 days, FDA announced in the Jan. 2 Federal Register. Alcon is seeking a 522-day patent extension for the drug, which was approved Aug. 30.